The University of Chicago Header Logo

Connection

Mark J. Ratain to Biotransformation

This is a "connection" page, showing publications Mark J. Ratain has written about Biotransformation.
Connection Strength

0.203
  1. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol. 2002 Jan 01; 20(1):7-8.
    View in: PubMed
    Score: 0.053
  2. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52.
    View in: PubMed
    Score: 0.053
  3. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
    View in: PubMed
    Score: 0.037
  4. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
    View in: PubMed
    Score: 0.024
  5. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
    View in: PubMed
    Score: 0.022
  6. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.